Rare Disease Drug Acquisition
LEO Pharma Acquires Global Rights for Dersimelagon, Advancing Rare Skin Disease Treatment
Danish drugmaker LEO Pharma has agreed to buy worldwide rights to dersimelagon, an experimental oral drug, from Japan's Tanabe Pharma for up to $435 million, according to Reuters. The deal includes upfront payments, near-term milestone payments, and tiered royalties on future net sales.
Dersimelagon targets two rare genetic skin disorders — erythropoietic protoporphyria (EPP) and X-linked protoporphyria. Both conditions cause extreme sensitivity to light. If approved, it would be the first oral treatment available for either disease, Reuters reported.
What Dersimelagon Does and Why It Matters
EPP and X-linked protoporphyria are rare inherited disorders. People with these conditions cannot tolerate sunlight without severe pain. Current treatments are limited and often require injections or infusions. An oral pill would mark a major step forward for patients.
Dersimelagon works by targeting a specific pathway that reduces the body's overreaction to light. It is still experimental, meaning it has not yet received regulatory approval. LEO Pharma is betting it can get it over the finish line and bring the first oral option to market, according to Reuters.
LEO Pharma Pushes Deeper Into Rare Skin Diseases
The acquisition fits squarely into LEO Pharma's broader strategy to expand beyond common skin conditions like psoriasis and eczema. The Danish company wants a stronger foothold in rare genetic skin diseases, a faster-growing and higher-value part of the dermatology market.
In the first half of 2026, LEO Pharma reported 10% revenue growth at constant exchange rates, driven by its dermatology portfolio, Voice of Alexandria reported. The company also noted improved gross margins and increased spending on both commercial activities and innovation.
Deal Terms: $435 Million With Strings Attached
The total deal value of up to $435 million is not all paid upfront. It breaks down into an upfront fee, near-term milestone payments tied to development progress, and longer-term milestone payments linked to commercial success, according to Market Screener.
LEO Pharma will also pay Tanabe Pharma tiered royalties based on net sales if dersimelagon reaches the market. That structure means Tanabe keeps a financial stake in the drug's long-term success even after handing over worldwide rights.
Tanabe Pharma Exits, LEO Pharma Takes the Wheel
Tanabe Pharma, a Japanese drugmaker, had been developing dersimelagon but chose to out-license the worldwide rights rather than commercialize it globally on its own. That is a common move for mid-sized pharmaceutical companies facing the high cost of global drug launches.
LEO Pharma now takes on full responsibility for development, regulatory filings, and commercialization worldwide. The company has not yet disclosed a timeline for when it expects to seek regulatory approval, according to Reuters.
Sentiment
NeutralPublishers
4
Articles
3
Reach
4
